MannKind (MNKD) announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective September 29. Dr. Ahuja will report directly to Michael Castagna, PharmD, CEO, and will serve on the company’s executive leadership team. Dr. Ahuja brings to MannKind more than two decades of leadership experience across the biopharmaceutical industry, spanning development-stage companies and global pharmaceutical firms since 2003. Most recently, he served as the Development and Launch Leader for a late-stage DNA-based therapeutic at Kardigan Bio, a cardiology-focused biopharmaceutical company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNKD:
- MannKind Corporation’s Phase 3 Study: A Potential Game-Changer for Nontuberculous Mycobacterial Infections
- MannKind price target raised to $15 from $12 at Oppenheimer
- Positive TETON-2 Study Results Drive Buy Rating and Price Target Increase for MannKind
- MannKind price target raised to $11 from $9 at H.C. Wainwright
- Unusually active option classes on open September 2nd